FDA Officially Approves First Acetaminophen-Naproxen Combination Product

The U.S. Food and Drug Administration (FDA) has officially approved Kenvue's (KVUE) fixed-dose combination (FDC) product, 'Tylenol with Naproxen,' containing acetaminophen and naproxen sodium, for over-the-counter (OTC) use. This NDA 219962 approval represents a significant milestone in the U.S. OTC analgesic category, as it is the first product to combine these two ingredients. Kenvue will gain marketing exclusivity in the U.S. market for the next three years. This will prevent generic and competing products from entering the market, allowing Kenvue to quickly establish a dominant position.

Synergistic Dual-Action Mechanism Proven in Eight Clinical Trials

This approval is based on data from a total of eight large-scale clinical trials that objectively demonstrated the synergistic effects and long-term safety profile of the two analgesic ingredients. Each tablet contains 325mg of acetaminophen and 110mg of naproxen sodium. When taken as two tablets (total 650mg/220mg) at a time for adults, the analgesic effect lasts for up to 12 hours. The combination of acetaminophen, which provides rapid onset of action (within 30 minutes), and naproxen sodium, which provides long-term anti-inflammatory and analgesic effects, offers superior clinical benefits compared to single-ingredient products. It also helps to prevent potential drug abuse and adverse effects, such as liver damage, that can occur when individual medications are taken together.

Kenvue's Strategy to Strengthen its Core Cash Cow After the Spin-Off

For Kenvue, which has established its independent portfolio after spinning off from Johnson & Johnson, this FDA approval will be a strategic milestone in extending the lifespan of the Tylenol brand. The company plans to solidify its market leadership by adding a premium, high-margin new product to the Tylenol line, which currently generates approximately $2 billion in annual retail sales, accounting for about 8-10% of the company's total revenue. In particular, this FDC approval is not just a simple line extension, but also a demonstration of Kenvue's independent research and development capabilities in the trend of prescription-to-OTC switches. The success of this new product will be a key factor in evaluating Kenvue's independent corporate value and stock price growth potential, especially in light of recent structural changes, including private equity investments.

Fierce Competition in the $10 Billion U.S. Analgesic Market

Currently, the U.S. OTC analgesic market is valued at approximately $9.82 billion as of 2025 and continues to grow steadily, driven by an aging population and a preference for non-opioid analgesics. Tylenol with Naproxen will compete strongly with Haleon's 'Advil Dual Action' (acetaminophen + ibuprofen), which has already established a presence in the market. The advantage of naproxen sodium, which has a longer half-life than ibuprofen and provides 12 hours of relief, is expected to appeal to patients with chronic musculoskeletal pain or arthritis. Kenvue plans to further consolidate its market dominance in the U.S. analgesic market, which is growing at a compound annual growth rate (CAGR) of approximately 3.84%, with this new product.

Changes in Safety Warning Labeling and Pharmacy Counseling

With the FDA approval, the product packaging will include prominent warnings about the risk of acute hepatotoxicity from acetaminophen overdose and the gastrointestinal and cardiovascular risks associated with naproxen, an NSAID. In addition, safety measures, such as restrictions on use by pregnant women after 20 weeks of gestation, have been refined, requiring careful attention when consumers use the product themselves. Distribution channels and pharmacies will begin providing proper counseling and distributing informational materials to ensure that consumers are aware that they are taking two potent analgesic ingredients simultaneously. The establishment of these safety management guidelines will be a key factor in determining the initial sales growth and long-term market success of the new product.